Published on 02/12/2025

QS for Single-Use: Records and Governance

In the increasingly complex landscape of biologics and advanced therapy medicinal products (ATMPs), the necessity for comprehensive quality standards (QS) for single-use systems cannot be overstated. This article serves as a thorough guide to understanding the records and governance surrounding these systems, focusing on key areas such as viral clearance validation, spiking studies, and adherence to regulatory requirements set forth by authorities such as the FDA, EMA, and MHRA. Each aspect covered is crucial for ensuring compliance with EMA regulations and the stringent requirements of aseptic controls as outlined in Annex 1.

Understanding Aseptic Techniques in Single-Use Systems

Single-use systems (SUS) represent a significant innovation in the pharmaceutical industry, particularly for aseptic processing. However, ensuring that these systems maintain robust aseptic conditions is critical. This section elaborates on the principles of aseptic techniques as they apply to single-use systems, emphasizing best practices, risk management strategies, and compliance with regulatory documentation.

Key Principles of Aseptic Processing

• Aseptic Environment: Ensuring an environmentally controlled space with appropriate air quality and particulate matter control.
• Germ-Free Components: Utilizing sterilized single-use components that minimize the risk of contamination.
• Personnel Training: Providing comprehensive training to staff involved in aseptic handling to mitigate human-factor related risks.

Each element must be documented thoroughly, producing a clear record of compliance with aseptic guidelines. Regulatory bodies stress the importance of these documents as they provide a chain of identity custody, which is essential for maintaining product integrity.

Viral Clearance Validation: Essentials and Methodology

Viral clearance validation is a critical step in the development of biologics, particularly for those produced using single-use systems. This process ensures that any potential viral contaminants are adequately reduced or eliminated during production. In line with quality standards, an exhaustive understanding of the viral clearance methodology is essential.

The Role of Spiking Studies

Spiking studies are foundational in determining the efficacy of a viral clearance process. These studies involve the deliberate introduction of viral contaminants into a batch of therapeutic material to assess the system’s ability to eliminate these pathogens. The results generated from spiking studies contribute significantly to the validation of viral clearance procedures.

Implementation of Viral Clearance Strategies

• Selection of Viruses: Choose representative viruses that are relevant to the product type for validation.
• Establishing Limits: Define acceptable limits for viral load reduction based on product characteristics.
• Monitoring: Conduct routine assessments throughout production to ensure persistent adherence to viral clearance protocols.

Moreover, maintaining meticulous records of these studies is of utmost importance, both as a safeguard against contamination and as a demonstration of compliance with FDA regulations concerning process validation. The guidelines set forth in ICH Q5A(R2) further detail the expectations surrounding viral clearance validation.

Closed Systems and Their Impact on Aseptic Processes

Closed systems are designed to eliminate the exposure of drug products to the environment during manufacturing and handling. Within the context of aseptic controls, closed systems play a pivotal role in maintaining sterility and ensuring product safety.

Benefits of Closed Systems

• Reduced Contamination Risk: By preventing contact with external environments, closed systems inherently reduce the risk of contamination.
• Integrity of the Manufacturing Process: These systems maintain integrity throughout the production process, facilitating traceability and documentation.
• Streamlined Implementation: Closed systems often allow for faster implementation and can be seamlessly integrated into existing manufacturing workflows.

Challenges in Closed System Implementation

Despite their advantages, closed systems come with challenges that must be addressed in validation and operation:

• Complexity of Validation: The closed nature can complicate the validation process, necessitating more comprehensive testing and documentation.
• Supply Chain Considerations: Ensuring the availability of qualified suppliers for closed components adds an additional layer of complexity.

All aspects of closed systems must be governed by stringent procedures that outline the necessary validation steps, further establishing a clear pathway to approval by regulatory agencies.

Establishing Chain of Identity Custody (COC) and Chain of Identity (COI)

The integrity of biologics is largely maintained through the establishment of a robust chain of identity custody (COC) and chain of identity (COI). These systems ensure that every component involved in the production of biologics is tracked and verified throughout the manufacturing process.

Implementing Chain of Identity Custody

• Documentation Protocols: Develop protocols for documenting each step in the production process, ensuring traceability of raw materials through to finished products.
• Identification Methods: Utilize identification technologies such as RFID or barcoding to facilitate accurate tracking.
• Regular Audits: Conduct audits of processes to confirm compliance with established identity custody protocols.

These measures not only help in adhering to regulatory requirements but also enhance the overall quality assurance processes for manufacturers focusing on ATMPs.

Process Performance Qualification (PPQ) and Continuous Process Verification (CPV) Tailoring for ATMP

PPQ and CPV are critical components of process validation. For ATMP products, tailoring these elements appropriately is vital due to the unique challenges that come with their development and production.

Tailoring the PPQ Process

In the context of ATMPs, PPQ must be focused on the characteristics of the product, which can differ significantly from traditional pharmaceuticals. This customization allows for a focused approach that aligns with the critical quality attributes (CQAs) relevant to potency and identity.

Continuous Process Verification Practices

• Real-Time Data Monitoring: Implement real-time data collection systems to monitor and validate critical parameters during the manufacturing process.
• Feedback Mechanisms: Develop feedback systems that allow for rapid adjustments based on monitoring data.
• Comprehensive Reporting: Maintain thorough records of CPV activities, supporting ongoing compliance with regulatory expectations.

By adopting tailored PPQ and CPV strategies, manufacturers can enhance the robustness of their validation processes, ensuring that products meet stringent quality standards throughout their lifecycle.

Conclusion: Aligning with Regulatory Standards

As the landscape of biologics and ATMPs evolves, pharmaceutical professionals must adhere to regulations set forth by authorities like the FDA, EMA, and MHRA. Developing comprehensive validation strategies for single-use systems is vital for achieving compliance and ensuring patient safety.

This guide has outlined essential elements of aseptic controls, viral clearance validation, the integration of closed systems, and the importance of implementing strong governance structures. By following these practices, professionals involved in quality assurance and regulatory affairs can mitigate risks and contribute to the overall success of their organizations in this challenging environment.